Literature DB >> 34202178

Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies.

Clara J Sei1, Mangala Rao2, Richard F Schuman3, Luke T Daum4, Gary R Matyas2, Nimisha Rikhi1, Kevin Muema1, Alexander Anderson2,5, Ousman Jobe2,6, Kellie A Kroscher1, Carl R Alving2, Gerald W Fischer1.   

Abstract

A universal influenza candidate vaccine that targets multiple conserved influenza virus epitopes from hemagglutinin (HA), neuraminidase (NA) and matrix (M2e) proteins was combined with the potent Army liposomal adjuvant (ALFQ) to promote induction of broad immunity to seasonal and pandemic influenza strains. The unconjugated and CRM-conjugated composite peptides formulated with ALFQ were highly immunogenic and induced both humoral and cellular immune responses in mice. Broadly reactive serum antibodies were induced across various IgG isotypes. Mice immunized with the unconjugated composite peptide developed antibody responses earlier than mice immunized with conjugated peptides, and the IgG antibodies were broadly reactive and neutralizing across Groups 1 and 2 influenza viruses. Multi-epitope unconjugated influenza composite peptides formulated with ALFQ provide a novel strategy for the development of a universal influenza vaccine. These synthetic peptide vaccines avoid the pitfalls of egg-produced influenza vaccines and production can be scaled up rapidly and economically.

Entities:  

Keywords:  ALFQ; QS21 (also known as QS-21); Th1/Th2 responses; broadly reactive antibodies; immune responses; influenza; liposomes; neutralizing antibodies; peptides; universal vaccine

Year:  2021        PMID: 34202178     DOI: 10.3390/vaccines9070698

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  21 in total

1.  Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada.

Authors:  Yacine Abed; Isabelle Hardy; Yan Li; Guy Boivin
Journal:  J Med Virol       Date:  2002-08       Impact factor: 2.327

2.  Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.

Authors:  Yao-Qing Chen; Teddy John Wohlbold; Nai-Ying Zheng; Min Huang; Yunping Huang; Karlynn E Neu; Jiwon Lee; Hongquan Wan; Karla Thatcher Rojas; Ericka Kirkpatrick; Carole Henry; Anna-Karin E Palm; Christopher T Stamper; Linda Yu-Ling Lan; David J Topham; John Treanor; Jens Wrammert; Rafi Ahmed; Maryna C Eichelberger; George Georgiou; Florian Krammer; Patrick C Wilson
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

Review 3.  Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides.

Authors:  C R Alving; V Koulchin; G M Glenn; M Rao
Journal:  Immunol Rev       Date:  1995-06       Impact factor: 12.988

Review 4.  Tracking progress in universal influenza vaccine development.

Authors:  Julie Ostrowsky; Meredith Arpey; Kristine Moore; Michael Osterholm; Martin Friede; Jennifer Gordon; Deborah Higgins; Julia Molto-Lopez; Jonathan Seals; Joseph Bresee
Journal:  Curr Opin Virol       Date:  2020-04-09       Impact factor: 7.090

5.  Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.

Authors:  Wei Wang; Qiong Chen; Lauren A Ford-Siltz; Leah C Katzelnick; Gabriel I Parra; Hyo Sook Song; Russell Vassell; Carol D Weiss
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

6.  Antibody recognition of a highly conserved influenza virus epitope.

Authors:  Damian C Ekiert; Gira Bhabha; Marc-André Elsliger; Robert H E Friesen; Mandy Jongeneelen; Mark Throsby; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2009-02-26       Impact factor: 47.728

Review 7.  Peptide-based synthetic vaccines.

Authors:  Mariusz Skwarczynski; Istvan Toth
Journal:  Chem Sci       Date:  2015-12-17       Impact factor: 9.825

8.  Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant.

Authors:  Oscar B Torres; Gary R Matyas; Mangala Rao; Kristina K Peachman; Rashmi Jalah; Zoltan Beck; Nelson L Michael; Kenner C Rice; Arthur E Jacobson; Carl R Alving
Journal:  NPJ Vaccines       Date:  2017-05-02       Impact factor: 7.344

Review 9.  The Next Generation of Influenza Vaccines: Towards a Universal Solution.

Authors:  Christopher L D McMillan; Paul R Young; Daniel Watterson; Keith J Chappell
Journal:  Vaccines (Basel)       Date:  2021-01-07

Review 10.  M2e-Based Universal Influenza A Vaccines.

Authors:  Lei Deng; Ki Joon Cho; Walter Fiers; Xavier Saelens
Journal:  Vaccines (Basel)       Date:  2015-02-13
View more
  1 in total

1.  Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development.

Authors:  Mengling Li; Pengju Guo; Cen Chen; Helong Feng; Wanpo Zhang; Changqin Gu; Guoyuan Wen; Venigalla B Rao; Pan Tao
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.